Immunization Monitoring Program, Active: A model of active surveillance of vaccine safety

Seminars in Pediatric Infectious Diseases

Volumn 14, Issue 3, 2003, Pages 213-219

  Scheifele, David W ⁱ   Halperin, Scott A ^a   Morris, Robert ^b   Déry, Pierre ^l   Lebel, Marc ^c   Moore, Dorothy ^l   Le Saux, Nicole ^d   Ford Jones, Lee ^e   Law, Barbara ^l   Tan, Ben ^f   Jadavji, Taj ^g   Kellner, James ^g   Vaundry, Wendy ^h   King, Arlene ^j   Walop, Wikke ^j   Waters, John ^k  

^a IWK HEALTH CENTRE   (Canada)

^b New Janeway Childrens Health and Rehabilitation Centre   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f ROYAL UNIVERSITY HOSPITAL   (Canada)

^g ALBERTA CHILDREN'S HOSPITAL   (Canada)

^h STOLLERY CHILDREN S HOSPITAL   (Canada)

ⁱ BC CHILDREN S HOSPITAL   (Canada)

^j LAB CENTRE FOR DISEASE CONTROL   (Canada)

^k Alberta Health   (Canada)

^l BC's Children's Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; VACCINE;

ABSCESS; ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; BRAIN DISEASE; CANADA; CHILD; DRUG SAFETY; FLACCID PARALYSIS; HEALTH SURVEY; HUMAN; IMMUNIZATION; INFLUENZA; MEASLES; MUMPS; MUSCLE HYPOTONIA; NEWBORN; NURSE; OUTCOMES RESEARCH; PATIENT MONITORING; PERTUSSIS; RISK ASSESSMENT; RUBELLA; SEIZURE; THROMBOCYTOPENIA; TUBERCULOSIS; VACCINATION REACTION;

EID: 0042521128     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1870(03)00036-0     Document Type: Article

References (29)

1. McDonald JC, Moore DL, Quennec P: Clinical and epidemiological features of mumps meningoencephalitis and possible vaccine-related disease. Pediatr Infect Dis J 8:751-755, 1989
2. Anonymous: Synopsis of a workshop on post-marketing surveillance of vaccine-associated adverse events. Can Dis Wkly Rep 17:97-98, 1991
3. Morris R, Halperin SA, Déry P, et al: IMPACT monitoring network: A better mousetrap. Can J Infect Dis 4:194-195, 1993
4. Immunization Monitoring Program, Active (IMPACT): Recent trends in pediatric Haemophilus influenzae type b infections in Canada. Can Med Assoc J 154:1041-1047, 1996
5. Scheifele DW, Gold R, Marchessault V, et al: Failures after immunization with Haemophilus influenzae type b vaccines, 1991-1995. Can Commun Dis Rep 22:17-23, 1996
6. Scheifele DW, Halperin SA, Vaudry W, et al: Historic low Haemophilus influenzae type b case tally - Canada, 2000. Can Commun Dis Rep 27:149-150, 2001
7. Scheifele DW, Bell A, Jadavji T, et al: Population-based surveillance of Haemophilus influenzae type b invasive infections in children in British Columbia, Alberta and Ontario: 1995-1997. Can J Infect Dis 11:135-140, 2000
8. Doherty J, Grenier D: The Canadian Paediatric Surveillance Program: Beyond collecting numbers. J Paediatr Child Health 6:269-270, 2001
9. Scheifele DW, Law B, Jadavji T, et al: Disseminated Bacille Calmette-Guérin infection: Three recent Canadian cases. Can Commun Dis Rep 24:69-72, 1998
10. Jadavji T, Scheifele D, Halperin S: Thrombocytopenia after immunization of Canadian children, 1992-2001. Pediatr Infect Dis J 22:119-122 2003
11. Cohn J: Thrombocytopenia in childhood: An evaluation of 433 patients. Scand J Hematol 16:226-240, 1976
12. Miller E, Wright P, Farrington P, et al: Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 84:227-229, 2001
13. Farrington P, Pugh S, Colville A, et al: A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345:567-569, 1995
14. Le Saux N, Barrowman N, Moore D, et al: Decrease in hospital admissions for febrile seizures and hypotonic-hyporesponsive episodes since switching to acellular pertussis vaccine in Canada: A report from IMPACT (submitted)
15. Uberall NA, Stehr K, Cherry JD, et al: Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Dev Biol Stand 89:83-89, 1997
16. Greco D, Salmaso S, Mastrantonio P, et al: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334:341-348, 1996
17. Rosenthal S, Chen R, Hadler S: The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine: A post marketing assessment. Arch Pediatr Adolesc Med 150:457-460, 1996
18. Jackson LA, Carste BA, Malais D, et al: Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J 21:781-785, 2002
19. Miller E: Collapse reactions after whole cell pertussis. BMJ 316:876, 1998
20. Cody CL, Baraff LJ, March SM, et al: Nature and rates of adverse reactions associated with DPT and DT immunizations in infants and children. Pediatrics 68:650-660, 1981
21. Gustafsson L, Hallander HO, Olin P, et al: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334:349-355, 1996
22. DuVernoy TS, Braun MM, VAERS Working Group: Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106:821-822, 2000
23. Moore DL, Le Saux N, Scheifele D, et al: Lack of evidence of encephalopathy related to pertussis vaccine: Active surveillance, Canada, 1993-2001. 2002 (abstract) Presented at the 5th Canadian National Immunization Conference, December 1-3, 2002, Victoria, British Columbia, Canada.
24. Griffen MR, Ray WA, Livengood JR, et al: Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med 319:618-623, 1988
25. Morishima T, Togashi T, Yokota S, et al: Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 35:512-517, 2002
26. Law B, MacDonald N, Halperin S, et al: The Immunization Monitoring Program, Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J 19:1053-1059, 2000
27. Halperin SA, Wang EL, Law B, et al: Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: Report of the Immunization Monitoring Program - Active (IMPACT). Clin Infect Dis 28:1238-1243, 1999
28. Scheifele DW, Halperin SA, Pelletier L, et al: Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies. Clin Infect Dis 31:58-64, 2000
29. Bjornson GL, Scheifele DW, Halperin SA, et al: Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. Pediatr Infect Dis J 21:947-950, 2002